The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, colorectal cancer, multiple myeloma, and sarcoma.
Opinion|Videos|May 14, 2026
Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)
Author(s)Paul D. Nathan, MBBS, PhD, FRCP
Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.
Updated findings from a phase 3 trial in metastatic uveal melanoma demonstrated that tebentafusp continued to show a durable overall survival benefit with long-term follow-up in previously untreated patients. The analysis also highlighted that early ctDNA clearance may serve as a more sensitive indicator of treatment activity than conventional radiographic response assessments. Additionally, continued treatment beyond radiographic progression was associated with improved post-progression outcomes in selected patients.
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
The OncFive: Top Oncology Articles for the Week of 6/28
3
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5